There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
1 response
9,228 views
0 reactions
|
by Bukowski
02-25-2017, 04:46 AM
|
|||
|
1 response
9,975 views
0 reactions
|
12-13-2016, 03:39 AM
|
|||
|
3 responses
10,331 views
0 reactions
|
12-12-2016, 03:15 PM
|
|||
|
1 response
9,716 views
0 reactions
|
10-04-2016, 12:39 PM
|
|||
|
2 responses
10,598 views
0 reactions
|
by GenoMax
09-20-2016, 03:23 AM
|
|||
|
2 responses
9,716 views
0 reactions
|
by GenoMax
09-07-2016, 01:19 AM
|
|||
|
7 responses
10,219 views
0 reactions
|
by AllSeq
09-03-2016, 12:11 PM
|
|||
|
1 response
9,746 views
0 reactions
|
by zsmith
07-22-2016, 08:48 AM
|
|||
|
8 responses
12,678 views
0 reactions
|
by zsmith
07-22-2016, 08:43 AM
|
|||
|
1 response
9,908 views
0 reactions
|
by GenoMax
04-18-2016, 09:11 AM
|
No topics found.
-
Next-generation sequencing (NGS) is now central to outbreak investigations and antimicrobial resistance tracking. Through sophisticated...07-31-2026, 07:00 AM
-
The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.
This convergence of genetics, immunology, and computation...09-01-2026, 05:41 AM -
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM
